Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Circumventing De Novo and Acquired Resistance to Trastuzumab: New Hope for the Care of ErbB2-Positive Breast Cancer

Published:2008-03 Issue: Volume:8 Page:S100-S113
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Piccart Martine

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference90 articles.

1. The ErbB signaling network: receptor heterodimerization in development and cancer;Olayioye;Embo J,2000

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors;Garrett;Mol Cell,2003

4. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling;Yu;Mol Biol Cell,2002

5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer;Drug Resistance Updates;2024-03

2. Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology;Heliyon;2024-02

3. Alpha-crystallin B chains in trastuzumab-resistant breast cancer cells promote endothelial cell tube formation through activating mTOR;Biochemical and Biophysical Research Communications;2022-01

4. Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer;Oncology Research and Treatment;2022

5. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib;Cancer Letters;2020-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3